{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T17:47:42Z","timestamp":1762278462188,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.vaccine.2025.126955","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:08:42Z","timestamp":1741565322000},"page":"126955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron"],"prefix":"10.1016","volume":"53","author":[{"given":"Wilhelmine","family":"Meeraus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail","family":"Postema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christen M.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre Santa","family":"Maria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e1rbara Emoingt","family":"Furtado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Conde-Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Ouwens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas Andreas","family":"Valverde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00f3vis Arns","family":"da Cunha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre Naime","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Corte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.vaccine.2025.126955_bb0005","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: a mathematical modelling study","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126955_bb0015","volume":"14","author":"Townsend","year":"2023","journal-title":"Seasonality of endemic COVID-19"},{"year":"2023","series-title":"Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic","author":"World Health Organization (WHO)","key":"10.1016\/j.vaccine.2025.126955_bb0025"},{"issue":"15","key":"10.1016\/j.vaccine.2025.126955_bb0030","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2119893119","article-title":"COVID-19 therapeutics: challenges and directions for the future","volume":"119","author":"Robinson","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2025.126955_bb0035","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/infdis\/jiad181","article-title":"The burden of COVID-19 in the immunocompromised patient: implications for vaccination and needs for the future","volume":"228","author":"Antinori","year":"2023","journal-title":"J Infect Dis"},{"issue":"26","key":"10.1016\/j.vaccine.2025.126955_bb0040","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1016\/j.vaccine.2023.05.030","article-title":"Uncovering inequities in Covid-19 vaccine coverage for adults and elderly in Brazil: a multilevel study of 2021-2022 data","volume":"41","author":"Boing","year":"2023","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126955_bb0045","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1186\/s12877-023-04236-y","article-title":"In-hospital mortality of older patients with COVID-19 throughout the epidemic waves in the great Paris area: a multicenter cohort study","volume":"23","author":"Thietart","year":"2023","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.vaccine.2025.126955_bb0050","first-page":"35:100747","article-title":"Impact of COVID-19 on immunocompromised populations during the omicron era: insights from the observational population-based INFORM study","author":"Evans","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126955_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(21)00219-6","article-title":"The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study","volume":"2","author":"Townsend","year":"2021","journal-title":"Lancet Microbe"},{"issue":"10","key":"10.1016\/j.vaccine.2025.126955_bb0060","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.3201\/eid1310.070576","article-title":"Duration of antibody responses after severe acute respiratory syndrome","volume":"13","author":"Wu","year":"2007","journal-title":"Emerg Infect Dis"},{"issue":"10328","key":"10.1016\/j.vaccine.2025.126955_bb0065","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126955_bb0070","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa2115481","article-title":"Duration of protection against mild and severe disease by Covid-19 vaccines","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2025.126955_bb0075","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S1473-3099(23)00365-1","article-title":"Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study","volume":"23","author":"Kirsebom","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126955_bb0080","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1038\/s41467-022-31839-7","article-title":"Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the omicron period in Brazil","volume":"13","author":"Cerqueira-Silva","year":"2022","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.vaccine.2025.126955_bb0085","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S1473-3099(23)00122-6","article-title":"Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study","volume":"23","author":"Arbel","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2025.126955_bb0090","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJMc2215471","article-title":"Effectiveness of bivalent boosters against severe omicron infection","volume":"388","author":"Lin","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2025.126955_bb0095","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2023.28.7.2300087","article-title":"Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 omicron infection, the Netherlands, September to December 2022","volume":"28","author":"Huiberts","year":"2023","journal-title":"Euro Surveill"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126955_bb0100","first-page":"1089","article-title":"Effectiveness of BNT162b2 BA.4\/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study. Lancet","volume":"11","author":"Tartof","year":"2023","journal-title":"Respir Med"},{"issue":"21","key":"10.1016\/j.vaccine.2025.126955_bb0105","doi-asserted-by":"crossref","first-page":"579","DOI":"10.15585\/mmwr.mm7221a3","article-title":"Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising conditions - VISION network, September 2022-April 2023","volume":"72","author":"Link-Gelles","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2025.126955_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2023.100755","article-title":"Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. And XBB.1.5 in England","author":"Kirsebom","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.vaccine.2025.126955_bb0115","unstructured":"World Health Organization (WHO). COVID-19 Vaccines with WHO Emergency Use Listing. Availible at: https:\/\/extranet.who.int\/prequal\/vaccines\/covid-19-vaccines-who-emergency-use-listing; Accessed 20 September 2024."},{"year":"2023","series-title":"Good practice statement on the use of variant-containing COVID-19 vaccines","author":"World Health Organization (WHO)","key":"10.1016\/j.vaccine.2025.126955_bb0120"},{"issue":"10278","key":"10.1016\/j.vaccine.2025.126955_bb0125","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(21)00306-8","article-title":"Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment","volume":"397","author":"Wouters","year":"2021","journal-title":"Lancet"},{"issue":"42","key":"10.1016\/j.vaccine.2025.126955_bb0130","doi-asserted-by":"crossref","first-page":"6366","DOI":"10.1016\/j.vaccine.2023.08.085","article-title":"COVID-19 vaccine booster doses provide increased protection against COVID-19 hospitalization compared with previously vaccinated individuals: interim findings from the REFORCO-Brazil real-world effectiveness study during Delta and omicron","volume":"41","author":"Meeraus","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126955_bb0135","unstructured":"Brazil Ministry of Health. NOTA T\u00c9CNICA N\u00b0 37\/2022-SECOVID\/GAB\/SECOVID\/MS. Available at: https:\/\/www.gov.br\/saude\/pt-br\/coronavirus\/vacinas\/plano-nacional-de-operacionalizacao-da-vacina-contra-a-covid-19\/notas-tecnicas\/2022\/nota-tecnica-37-2022-segunda-dose-de-reforco-em-trabalhadores-da-saude-retificada.pdf\/view; Accessed 10 February 2023."},{"year":"2022","series-title":"NOTA T\u00c9CNICA N\u00b0 176\/2022","author":"Brazil Ministry of Health","key":"10.1016\/j.vaccine.2025.126955_bb0140"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126955_bb0145","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac698","article-title":"Absolute and relative vaccine effectiveness of primary and booster series of COVID-19 vaccines (mRNA and adenovirus vector) against COVID-19 hospitalizations in the United States","volume":"10","author":"Lewis","year":"2023","journal-title":"Open Forum Infect Dis"},{"author":"Brazil Ministry of Health","key":"10.1016\/j.vaccine.2025.126955_bb0155"},{"key":"10.1016\/j.vaccine.2025.126955_bb0160","unstructured":"Brazil Ministry of Health. Recomenda\u00e7\u00f5es sobre a utiliza\u00e7\u00e3o do teste r\u00e1pido para detec\u00e7\u00e3o de ant\u00edgenos do SARS-CoV-2. Available at: https:\/\/www.saude.go.gov.br\/files\/\/banner_coronavirus\/protocolos-notas\/Notas%20T%C3%A9cnicas%20da%20Superintend%C3%AAncia%20de%20Vigil%C3%A2ncia%20em%20Sa%C3%BAde\/2022\/Nota%20T%C3%A9cnica%20n%C2%BA%2006.2022%20-%20Recomenda%C3%A7%C3%B5es%20sobre%20a%20%20utiliza%C3%A7%C3%A3o%20do%20teste%20r%C3%A1pido%20para%20detec%C3%A7%C3%A3o%20de%20ant%C3%ADgenos%20do%20SARS-CoV-2.pdf. Accessed 17 March 2023."},{"issue":"7","key":"10.1016\/j.vaccine.2025.126955_bb0165","article-title":"Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection","volume":"7","author":"Dinnes","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.vaccine.2025.126955_bb0185","first-page":"12631","article-title":"Reduction in severity and mortality in COVID-19 patients owing to heterologous third and fourth-dose vaccines during the periods of delta and omicron predominance in Thailand","author":"Intawong","year":"2023","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126955_bb0190","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1038\/s41467-022-33169-0","article-title":"Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against omicron in Brazil","volume":"13","author":"Ranzani","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126955_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14760584.2023.2143347","article-title":"Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic","volume":"22","author":"Solante","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.126955_bb0200","article-title":"Effectiveness of the fourth dose of COVID-19 vaccines against severe COVID-19 among adults 40 years or older in Brazil: a population-based cohort study","author":"Lazar Neto","year":"2024","journal-title":"Lancet Reg Health Am"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126955_bb0205","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1016\/S2214-109X(22)00112-7","article-title":"Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study","volume":"10","author":"Jara","year":"2022","journal-title":"Lancet Glob Health"},{"year":"2023","series-title":"Vacinometro COVID-19","author":"Brazil Ministry of Health","key":"10.1016\/j.vaccine.2025.126955_bb0215"},{"year":"2023","series-title":"COVID-19 vaccine to be included in Brazilian immunization program. @agenciabrasil","author":"Agenciabrasil.","key":"10.1016\/j.vaccine.2025.126955_bb0220"},{"key":"10.1016\/j.vaccine.2025.126955_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2021.112614","article-title":"COVID-19 seasonality in temperate countries","author":"D\u2019Amico","year":"2022","journal-title":"Environ Res"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126955_bb0230","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12913-021-07376-2","article-title":"Brazilian private health system: history, scenarios, and trends","volume":"22","author":"Cruz","year":"2022","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126955_bb0235","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/jep.13888","article-title":"The test-negative design: opportunities, limitations and biases","volume":"30","author":"Meester","year":"2024","journal-title":"J Eval Clin Pract"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126955_bb0240","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S1473-3099(22)00801-5","article-title":"Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression","volume":"23","author":"Bobrovitz","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2025.126955_bb0245","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3390\/vaccines12080885","article-title":"COVID-19 vaccination and public health: addressing global, regional, and within-country inequalities","volume":"12","author":"Santangelo","year":"2024","journal-title":"Vaccines (Basel)"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2500252X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2500252X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T17:42:57Z","timestamp":1762278177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2500252X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":42,"alternative-id":["S0264410X2500252X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126955","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126955","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126955"}}